2013中国高血压防治指南（修订版）

converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med,2000,342:145-153.

19. 19. Brown MJ, Palmer CR, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Morbidity and

mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the international Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet,2000,356:366-372.

20. 20. Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists

compared with diuretics and beta-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem(NORDIL) study. Lancet,2000,356:359-364.

21. 21. Adler AL, Stratton IM, Nei HA, et al. Association of systolic blood pressure with macrovascular

and microvascular complications of type 2 diabetes (UKPDS 36):prospective observational study. BMJ,2000, 321:412-429.

22. 22. Gosse P, Sheridan DJ, Zannad F,et al. Regression of left ventricular hypertrophy in hypertensive

patients treated with indapamide SR 1.5 mg versus enalapril 20 mg; the LIVE study. J Hypertens,2000,18:1465-1475.

23. 23. 王文，刘力生，陶寿淇, 等. 我国大样本心血管病临床试验的回顾与展望. 中华心血管病杂志,2000,28（5）：

335-338.

24. 24. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure

in hypertensive participants of the hypertension Optimal Treatment (HOT) study. J Am Soc Nephrol,2001,12:218-225.

25. 25. Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult

Treatment Panel III). Executive Summary of The Third Report of The National Cholesterol Education Program(NCEP)JAMA,2001,285:2486-2497.

26. 26. PROGRESS Collaborative Study Group. Randomised trial of perindopril based blood pressure-lowering

regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet,2001,358:1033-1041.

27. 27. Terpstra WL, May JF, Smit AJ, et al. Long-term effects of amlodipine and lisinopril on left

ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens,2001,19:303-309.

28. 28. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium and

the dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med,2001,344:3-10.

29. 29. Xiang-Hua Fang, Longstreth WT, Shi-Chuo Li, et al. Longitudinal Study of Blood Pressure and Stroke

in over 37,000 People in China. Cerebrovasc Dis 2001;11:225-229.

30. 30. Chinese Cardiac Study Group (Liu Lisheng , Wang Wen). Long-term mortality in patients with

myocardial infarction: impact of early treatment with captopril for 4 weeks. Chinese Medical Journal,2001, 114(2): 115-118.

31. 31. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular

mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet,2002,360:1903-1913.

32. 32. 王文,邓卿,马丽媛,等. 降压治疗对脑卒中再发预防的研究——PROGRESS和PATS试验及其临床意义. 中国

医药导刊, 2002,4(5)：382.

33. 33. Kjeldsen SE, Dahl?f B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and

mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan

intervention for Endpoint reduction (LIFE)substudy. JAMA,2002,288:1491-1498.

34. 34. Dahl?f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan

Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet,2002,359:995-1003.

35. 35. Lindholm LH, Ibsen H, Dahl?f B, et al. Cardiovascular morbidity and mortality in patients with

diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet,2002,359:1004-1010.

36. 36. Wright JT, Bakris G, Greene T, et al. for the African American Study of Kidney Disease and

Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK Trial. JAMA, 2002,288:2421-2431. 37. 37. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes

in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA,2002,288:2998-3007.

38. 38. 中国肥胖问题工作组数据汇总分析协作组. 中国成人体重指数和腰围对相关疾病危险因素异常的预测价值:

适宜体重指数和腰围切点的研究.中华流行病学杂志,2002,23:5-10.

39. 39. The ALLHAT Officers and coordinators for the ALLHAT Collaborative Research Group. Major outcomes

in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA,2002, 288 (23):2981-2997.

40. 40. Guidelines Committee. 2003 European Society of Hypertension –European Society of Cardiology.

Guidelines for the management of arterial hypertension. Journal of Hypertension, 2003,21:1011-1053. 41. 41. World Health Organization, International Society of Hypertension Writing Group. 2003 World Health

Organization (WHO), International Society of Hypertension (ISH) statement on management of hypertension(Guidelines and recommendations). Journal of Hypertension, 2003,21: 1983-1992

42. 42. Lithell H, Hansson L, Skogg I, et al for the SCOPE Study Group. The Study on Cognition and Prognosis

in the Elderly (SCOPE). Principal results of a randomised double-blind intervention trial. J Hypertens,2003,21;875-886.

43. 43. 王文,刘力生. 血压水平与脑卒中再发的关系-1520例脑血管病患者随访4年.高血压杂

志,2003,11:106-108.

44. 44. 陈蕾,贾伟平,陈俊茜,等.上海市成人”代谢综合征”流行调查. 中华心血管病杂志，2003,31:909-912. 45. 45. Black HR, Elliot WJ, Grandist G, et al for the CONVINCE Research Group. Principal results of the

Controlled Onset Verapamil Investigation of cardiovascular Endpoints (CONVINCE) trial. JAMA,2003,289:2073-2082.

46. 46. International Society of Hypertension. Statement on the management of blood pressure in acute

stroke. J Hypertens,2003,21:665-672.

47. 47. The European on reduction of cardiac events with perindopril in stable coronary artery disease

investigators. Efficacy of perindopril in reduction cardiovascular events among with stabe coronary artery disease: randomized, double-blind, placebo-controlled, multicentre trial (the EUROPA study)[J] . Lancet, 2003, 362: 782-788.

48. 48. Sever PS, Dahl?f B, Poulter NR, et al for the ASCOT investigators. The prevention of coronary

events and stroke with atorvastatin in hypertensive subjects with average or below average cholesterol levels. The Anglo-Scandinavian Cardiac Outcomes Trial: Lipid Lowering Arm (ASCOT: LLA). Lancet,2003,361:1149-1158.

49. 49. 戴闺柱. 心力衰竭治疗的新问题：神经内分泌不协调. 中华心血管病杂志,2003,31:1-2.

50. 50. 顾东风,黄广勇,何江,等. 中国心力衰竭流行病学调查及其患病率. 中华心血管病杂志, 2003,31:3-6. 51. 51. 王文,刘力生,龚兰生,等.我国大样本随机临床试验治疗心脑血管病的效价评估. 中华心血管病杂

志,2003,31:24-28.

52. 52. 赵冬. 中国人群的血脂流行病学研究. 中华心血管病杂志,2003,31: 74-78. 53. 53. 吴兆苏. 我国心血管流行病学发展30年回顾. 中华心血管病杂志,2003,31:881-884. 54. 54. 刘国仗, 马文君. 高血压诊断和治疗研究进展. 中华心血管病杂志,2003,31:884-888. 55. 55. 周北凡. 从流行病学研究走向临床防治实践. 中华心血管病杂志,2003,31:891-892.

56. 56. 国家“十五”攻关“冠心病、脑卒中综合危险度评估及干预方案的研究”课题组.国人缺血性心血管病发病

危险的评估方法及简易评估工具的开发研究. 中华心血管病杂志, 2003,31:893-901.

57. 57. 张维忠. 中国健康人群动脉弹性功能参数研究. 中华心血管病杂志,2003,31(4):245-249.

58. 58. 彭峰,林金秀,曾开淇,等. 肥胖和高血压患者餐后甘油三酯代谢异常与胰岛素抵抗的关系. 中华心血管病

杂志, 2003,31(7):509-513.

59. 59. 纪宝华. 顽固性高血压治疗对策. 中华心血管病杂志, 2003,31(5):395-397.

60. 60. 吴锡桂,段秀芳,黄广勇. 我国老年人群单纯性收缩期高血压患病率及影响因素.中华心血管病杂

志,2003,31(6);456-459.

61. 61. 王宏宇,胡大一.脉压与冠状动脉病变严重性的关系研究.中华心血管病杂志,2003,31(2):83-86.

62. 62. 李新立,蒋素华,张海峰,等. 降压治疗对颈动脉内膜中层厚度和动脉顺应性影响的研究. 中华心血管病杂

志,2003,31(4):254-256.

63. 63. 倪永斌,张维忠,王宏宇,等. 高血压病脉搏波速度与脉压关系的研究. 中华心血管病杂

志,2003,31(4):257-259.

64. 64. 王薇,赵冬,刘静,等. 中国35~64岁人群心血管病危险因素与发病危险预测模型的前瞻性研究.中华心血管

病杂志,2003,31:902-908.

65. 65. 刘力生,张维忠,郝建生,等. 非洛地平缓释片在高血压治疗中的达标率和安全性研究.中华心血管病杂

志,2004,32(4):291-294.

66. 66. 王拥军. 高血压与脑卒中. 中华心血管病杂志,2004,32(6):574-576.

67. 67. 刘静, 赵冬,王薇,等. 中国多省市心血管病危险因素队列研究与美国弗莱明翰心脏研究结果的比较. 中华

心血管病杂志,2004,32(2):167-172.

68. 68. 武阳丰,王增武,高润霖. 中国医疗卫生人员高血压防治观念和防治知识调查. 中华心血管病杂

志,2004,32(3):264-269.

69. 69. 祝之明,周芳明,张刚,等.”代谢综合征”心血管重塑的特征.中华心血管病杂志,2004,32(9):819-820. 70. 70. 安宁,王馨,武阳丰,等. 北京市城乡社区卫生服务中心高血压防治现状的对比研究. 中华心血管病杂

志,2004,32(11):1021-1025.

71. 71. 王薇, 赵冬, 厚磊,等. 1331人基线血压水平及10年血压变化与颈动脉粥样硬化关系的研究. 中华心血管

病杂志,2004,32(11):1017-1020.

72. 72. 张怡,朱鼎良. 原发性高血压遗传学研究的策略和方法. 高血压杂志,2004,12(1):4-8.

73. 73. Poole-Wilson PA, Lubsen J, Kirwan BA, et al. Effect of long-acting nifedipine on mortality and

cardiovascular morbidity in patients with stable angina requiring treatment (ACTION):randomized controlled trial[J].Lancet, 2004,364(9437):849-857.

74. 74. 王文,马丽媛,刘明波.降低血压水平是预防心脑血管事件的关键.中国医药导刊，2004，6（4）：259-261. 75. 75. Lisheng Liu. The Study of hypertension in china. Blood Pressure,2004,13:72-74.

76. 76. WHO consultation. Appropriate body mass index for Asian population and is implications for policy

and intervention strategies. Lancet, 2004,363:157-116.

77. 77. Nissen SE, Tuzcy EM, Libby P, et al. Effect of antihypertensive agents on cardiovascular events

in patients with coronary disease and normal blood pressure. The CAMELOT study: a randomized controlled trial [J]. JAMA, 2004, 292(18):2217-2226.

78. 78. Julius S, Kjeldsen ES, Weber M, et al. the VALUE trial group Outcomes in hypertensive patients

at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet,2004,363(9426): 2022-2031.

79. 79. Braunwald E, Domanski MJ, Fowler SE, et al for the PEACE trial investigators.

Angiotensin-converting-enzyme inhibitors in stable coronary artery disease. [J]. N Engl J Med, 2005,351(20): 2058-2068.

80. 80. 周北凡,武阳丰,李莹,等.中国成人”代谢综合征”腰围切点的研究.中华心血管病杂志,2005,33(1):

81-85.

81. 81. 王文,马丽媛,李卫,等. ACE抑制剂降压治疗对心脑血管事件影响的随机临床试验的汇总评估. 高血压杂志，

2005,13:202-208.

82. 82. 孙佳艺,赵冬,王薇,等. 北京地区2740人的血压水平10年(1992-2002)变化情况.高血压杂志,

2005,13(2):115-119.

83. 83. 郭翼珍, 龚艳春, 章建梁, 等. 高血压病伴”代谢综合征”患者463例的干预治疗研究. 中华心血管病杂

志,2005,33(2):132-136.

84. 84. 刘力生，龚兰生，王文，代表降压治疗预防脑卒中再发研究协作组. 降压治疗对中国脑血管病患者脑卒中

再发预防的多中心随机双盲对照临床研究.中华心血管病杂志,2005,33（7）:613-617. 85. 85. 朱鼎良.

我国高血压基因研究十年回顾和几点建议.中华心血管病杂志，2005，33（7）:585-587.

86. 86. Jiang He, Dongfeng Gu, Xigui Wu, et al. Major Causes of Death among Men and Women in China. N

Engl J Med 2005; 353:1124--1134.

87. 87. Liu Lisheng，Zhang Yuqing , Liu Guozhang ,et al, for FEVER Study Group. The Felodipine Event

Reduction (FEVER) study : A randomized long-term placebo controlled trial in Chinese hypertensive patients—design and principle results. J Hypertens 2005,23 (suppl 2): S118